MARKET

IMRA

IMRA

Imara Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.42
-0.19
-3.46%
Opening 11:10 07/23 EDT
OPEN
5.73
PREV CLOSE
5.61
HIGH
5.79
LOW
5.40
VOLUME
62.99K
TURNOVER
--
52 WEEK HIGH
36.00
52 WEEK LOW
5.40
MARKET CAP
141.49M
P/E (TTM)
-2.1262
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 4d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 4d ago
21 Stocks Moving in Monday's Pre-Market Session
Gainers Creatd Inc (NASDAQ: CRTD) shares rose 33.9% to $4.27 in pre-market trading after dropping around 9% on Friday.
Benzinga · 4d ago
The Past Week's Notable Insider Buys Include Ring Energy, SentinelOne, SPACs And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Special purpose acquisition companies attracted some notable insider buying las week. A prominent hedge fund manager and two chief execut...
Benzinga · 5d ago
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
Mid-Afternoon Market Update: Dow Gains 50 Points; Imara Shares Plunge
Toward the end of trading Wednesday, the Dow traded up 0.15% to 34,942.77 while the NASDAQ rose 0.07% to 14,687.21. The S&P also rose, gaining 0.26% to 4,380.58.
Benzinga · 07/14 18:29
SNQA, USEG, HNRG among mid-day movers
Gainers: U.S. Energy (USEG) +73%.Wilhelmina International (WHLM) +50%.SGOCO Group (SGOC) +41%.Datasea (DTSS) +43%.Westwood Holdings (WHG) +20%.CorePoint Lodging (CPLG) +19%.AcelRx Pharmaceuticals (ACRX) +17%.Marine Petroleum Trust (MARPS) +14%.Verb Technol...
Seekingalpha · 07/14 16:52
Mid-Day Market Update: Aspen Group Drops Following Q4 Results; Datasea Shares Surge
Midway through trading Wednesday, the Dow traded up 0.05% to 34,907.35 while the NASDAQ rose 0.48% to 14,747.61. The S&P also rose, gaining 0.24% to 4,379.85.
Benzinga · 07/14 16:07
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMRA. Analyze the recent business situations of Imara Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMRA stock price target is 35.00 with a high estimate of 42.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 47
Institutional Holdings: 11.01M
% Owned: 42.14%
Shares Outstanding: 26.13M
TypeInstitutionsShares
Increased
13
406.76K
New
10
194.98K
Decreased
10
884.91K
Sold Out
3
371.15K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.32%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Rahul Ballal
Chief Financial Officer/Chief Operating Officer/Primary Contact
Michael Gray
Senior Vice President
Kenneth Attie
Senior Vice President
Lynette Hopkinson
Independent Director
David Bonita
Independent Director
Mark Chin
Independent Director
Edward Conner
Independent Director
Barbara Dalton
Independent Director
Carl Goldfischer
Independent Director
Sara Nayeem
Independent Director
Laura Williams
No Data
About IMRA
Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.

Webull offers kinds of Imara Inc stock information, including NASDAQ:IMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRA stock methods without spending real money on the virtual paper trading platform.